Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
This list of potential positions covers Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases in USA. Please note, we provide buy hold or sell recommendation only in the context of selected investment horizon assuming investor has average attitude towards taking risk. Please also consider using Portfolio Positions Ratings and Equity Ratings tools to further calibrate your research.
Story appears to be empty
Acceleron Pharma (XLRN)
The entity beta is close to zero. As returns on the market increase, Acceleron Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Acceleron Pharma is expected to be smaller as well. The beta indicator helps investors understand whether Acceleron Pharma moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Acceleron deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns. The firm currently falls under 'Large-Cap' category with a current market capitalization of 10.91 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Acceleron Pharma's market, we take the total number of its shares issued and multiply it by Acceleron Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
argenx NV ADR (ARGX)
The company has return on total asset (ROA) of (0.0685) % which means that it has lost $0.0685 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0854) %, meaning that it created substantial loss on money invested by shareholders. Argenx NV's management efficiency ratios could be used to measure how well Argenx NV manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.07 in 2024. Return On Capital Employed is likely to drop to -0.11 in 2024. At this time, Argenx NV's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 439.7 M in 2024, whereas Other Current Assets are likely to drop slightly above 99.6 M in 2024. The firm currently falls under 'Large-Cap' category with a current market capitalization of 22.08 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Argenx NV's market, we take the total number of its shares issued and multiply it by Argenx NV's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Net Debt
(1.93 Billion)
Argenx NV reported Net Debt of (2.03 Billion) in 2023
Array TechnologiesInc (ARRY)
The company has return on total asset (ROA) of 0.0795 % which means that it generated a profit of $0.0795 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2654 %, meaning that it created $0.2654 on every $100 dollars invested by stockholders. Array TechnologiesInc's management efficiency ratios could be used to measure how well Array TechnologiesInc manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.16 in 2024. Return On Capital Employed is likely to rise to 0.17 in 2024. At this time, Array TechnologiesInc's Non Currrent Assets Other are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 511.8 M in 2024, whereas Total Assets are likely to drop slightly above 1.6 B in 2024. The firm currently falls under 'Mid-Cap' category with a current market capitalization of 1.86 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Array TechnologiesInc's market, we take the total number of its shares issued and multiply it by Array TechnologiesInc's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be undervalued. Array TechnologiesInc shows a prevailing Real Value of $16.4 per share. The current price of the firm is $11.94. Our model approximates the value of Array TechnologiesInc from analyzing the firm fundamentals such as Profit Margin of 0.09 %, current valuation of 2.66 B, and Return On Equity of 0.27 as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor acquiring undervalued instruments and dropping overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
BeiGene (BGNE)
The company has return on total asset (ROA) of (0.124) % which means that it has lost $0.124 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2226) %, meaning that it created substantial loss on money invested by shareholders. BeiGene's management efficiency ratios could be used to measure how well BeiGene manages its routine affairs as well as how well it operates its assets and liabilities. As of April 25, 2024, Return On Tangible Assets is expected to decline to -0.16. In addition to that, Return On Capital Employed is expected to decline to -0.32. At present, BeiGene's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 215.8 M, whereas Non Currrent Assets Other are projected to grow to (17.8 M). The firm currently falls under 'Large-Cap' category with a current market capitalization of 16.09 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BeiGene's market, we take the total number of its shares issued and multiply it by BeiGene's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Short Long Term Debt Total
976.69 Million
At present, BeiGene's Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting.
Eagle Pharmaceuticals (EGRX)
The company has return on total asset (ROA) of 0.0663 % which means that it generated a profit of $0.0663 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0488 %, meaning that it created $0.0488 on every $100 dollars invested by stockholders. Eagle Pharmaceuticals' management efficiency ratios could be used to measure how well Eagle Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Eagle Pharmaceuticals' Return On Tangible Assets are fairly stable compared to the past year. Return On Capital Employed is likely to rise to 0.17 in 2024, whereas Return On Equity is likely to drop 0.14 in 2024. At this time, Eagle Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 262.5 M in 2024, whereas Other Current Assets are likely to drop slightly above 8.2 M in 2024. The entity currently falls under 'Micro-Cap' category with a current market capitalization of 58.96 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Eagle Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Eagle Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be overvalued. Eagle Pharmaceuticals shows a prevailing Real Value of $4.14 per share. The current price of the firm is $4.77. Our model computes the value of Eagle Pharmaceuticals from reviewing the firm fundamentals such as Shares Outstanding of 12.96 M, current valuation of 116.19 M, and Profit Margin of 0.05 % as well as analyzing its technical indicators and probability of bankruptcy. In general, most investors advise acquiring undervalued instruments and dropping overvalued instruments since, at some point, asset prices and their ongoing real values will submerge.
Immunomedics (IMMU)
The company has return on total asset (ROA) of (25.16) % which means that it has lost $25.16 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (100.04) %, meaning that it created substantial loss on money invested by shareholders. Immunomedics' management efficiency ratios could be used to measure how well Immunomedics manages its routine affairs as well as how well it operates its assets and liabilities. The entity currently falls under 'Large-Cap' category with a current market capitalization of 20.31 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Immunomedics's market, we take the total number of its shares issued and multiply it by Immunomedics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Karyopharm Therapeutics (KPTI)
The company has return on total asset (ROA) of (0.2705) % which means that it has lost $0.2705 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.9105) %, meaning that it created substantial loss on money invested by shareholders. Karyopharm Therapeutics' management efficiency ratios could be used to measure how well Karyopharm Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The Karyopharm Therapeutics' current Return On Equity is estimated to increase to 1.10, while Return On Tangible Assets are projected to decrease to (0.62). As of now, Karyopharm Therapeutics' Other Current Assets are increasing as compared to previous years. The Karyopharm Therapeutics' current Debt To Assets is estimated to increase to 0.76, while Total Assets are projected to decrease to under 238.3 M. The firm currently falls under 'Small-Cap' category with a current market capitalization of 126.95 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Karyopharm Therapeutics's market, we take the total number of its shares issued and multiply it by Karyopharm Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Today, the firm appears to be overvalued. Karyopharm Therapeutics secures a last-minute Real Value of $0.96 per share. The latest price of the firm is $1.09. Our model forecasts the value of Karyopharm Therapeutics from analyzing the firm fundamentals such as Return On Equity of -8.91, profit margin of (0.98) %, and Current Valuation of 243.48 M as well as examining its technical indicators and probability of bankruptcy. In general, most investors recommend purchasing undervalued stocks and trading away overvalued stocks since, at some point, asset prices and their ongoing real values will merge together.
Merrimack Pharmaceuticals (MACK)
The company has return on total asset (ROA) of (0.0697) % which means that it has lost $0.0697 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0622) %, meaning that it created substantial loss on money invested by shareholders. Merrimack Pharmaceuticals' management efficiency ratios could be used to measure how well Merrimack Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.06. Return On Capital Employed is expected to rise to -0.11 this year. Change To Liabilities is expected to rise to about 25.5 K this year, although the value of Total Current Liabilities will most likely fall to about 418.9 K. This firm currently falls under 'Small-Cap' category with a current market capitalization of 213.98 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Merrimack Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Merrimack Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Macroaxis financial leverage refers to using borrowed capital as a funding source to finance Macroaxis ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Macroaxis financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Macroaxis' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Macroaxis' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Macroaxis's total debt and its cash.
Macroaxis Gross Profit
Macroaxis Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Macroaxis previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Macroaxis Gross Profit growth over the last 10 years. Please check Macroaxis' gross profit and other fundamental indicators for more details.
Story appears to be empty
Acceleron Pharma (XLRN)
The entity beta is close to zero. As returns on the market increase, Acceleron Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Acceleron Pharma is expected to be smaller as well. The beta indicator helps investors understand whether Acceleron Pharma moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Acceleron deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns. The firm currently falls under 'Large-Cap' category with a current market capitalization of 10.91 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Acceleron Pharma's market, we take the total number of its shares issued and multiply it by Acceleron Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
argenx NV ADR (ARGX)
The company has return on total asset (ROA) of (0.0685) % which means that it has lost $0.0685 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0854) %, meaning that it created substantial loss on money invested by shareholders. Argenx NV's management efficiency ratios could be used to measure how well Argenx NV manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.07 in 2024. Return On Capital Employed is likely to drop to -0.11 in 2024. At this time, Argenx NV's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 439.7 M in 2024, whereas Other Current Assets are likely to drop slightly above 99.6 M in 2024. The firm currently falls under 'Large-Cap' category with a current market capitalization of 22.08 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Argenx NV's market, we take the total number of its shares issued and multiply it by Argenx NV's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Net Debt
(1.93 Billion)
Argenx NV reported Net Debt of (2.03 Billion) in 2023
Array TechnologiesInc (ARRY)
The company has return on total asset (ROA) of 0.0795 % which means that it generated a profit of $0.0795 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2654 %, meaning that it created $0.2654 on every $100 dollars invested by stockholders. Array TechnologiesInc's management efficiency ratios could be used to measure how well Array TechnologiesInc manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.16 in 2024. Return On Capital Employed is likely to rise to 0.17 in 2024. At this time, Array TechnologiesInc's Non Currrent Assets Other are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 511.8 M in 2024, whereas Total Assets are likely to drop slightly above 1.6 B in 2024. The firm currently falls under 'Mid-Cap' category with a current market capitalization of 1.86 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Array TechnologiesInc's market, we take the total number of its shares issued and multiply it by Array TechnologiesInc's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be undervalued. Array TechnologiesInc shows a prevailing Real Value of $16.4 per share. The current price of the firm is $11.94. Our model approximates the value of Array TechnologiesInc from analyzing the firm fundamentals such as Profit Margin of 0.09 %, current valuation of 2.66 B, and Return On Equity of 0.27 as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor acquiring undervalued instruments and dropping overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
BeiGene (BGNE)
The company has return on total asset (ROA) of (0.124) % which means that it has lost $0.124 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2226) %, meaning that it created substantial loss on money invested by shareholders. BeiGene's management efficiency ratios could be used to measure how well BeiGene manages its routine affairs as well as how well it operates its assets and liabilities. As of April 25, 2024, Return On Tangible Assets is expected to decline to -0.16. In addition to that, Return On Capital Employed is expected to decline to -0.32. At present, BeiGene's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 215.8 M, whereas Non Currrent Assets Other are projected to grow to (17.8 M). The firm currently falls under 'Large-Cap' category with a current market capitalization of 16.09 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BeiGene's market, we take the total number of its shares issued and multiply it by BeiGene's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Short Long Term Debt Total
976.69 Million
At present, BeiGene's Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting.
Eagle Pharmaceuticals (EGRX)
The company has return on total asset (ROA) of 0.0663 % which means that it generated a profit of $0.0663 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0488 %, meaning that it created $0.0488 on every $100 dollars invested by stockholders. Eagle Pharmaceuticals' management efficiency ratios could be used to measure how well Eagle Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Eagle Pharmaceuticals' Return On Tangible Assets are fairly stable compared to the past year. Return On Capital Employed is likely to rise to 0.17 in 2024, whereas Return On Equity is likely to drop 0.14 in 2024. At this time, Eagle Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 262.5 M in 2024, whereas Other Current Assets are likely to drop slightly above 8.2 M in 2024. The entity currently falls under 'Micro-Cap' category with a current market capitalization of 58.96 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Eagle Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Eagle Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be overvalued. Eagle Pharmaceuticals shows a prevailing Real Value of $4.14 per share. The current price of the firm is $4.77. Our model computes the value of Eagle Pharmaceuticals from reviewing the firm fundamentals such as Shares Outstanding of 12.96 M, current valuation of 116.19 M, and Profit Margin of 0.05 % as well as analyzing its technical indicators and probability of bankruptcy. In general, most investors advise acquiring undervalued instruments and dropping overvalued instruments since, at some point, asset prices and their ongoing real values will submerge.
Immunomedics (IMMU)
The company has return on total asset (ROA) of (25.16) % which means that it has lost $25.16 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (100.04) %, meaning that it created substantial loss on money invested by shareholders. Immunomedics' management efficiency ratios could be used to measure how well Immunomedics manages its routine affairs as well as how well it operates its assets and liabilities. The entity currently falls under 'Large-Cap' category with a current market capitalization of 20.31 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Immunomedics's market, we take the total number of its shares issued and multiply it by Immunomedics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Karyopharm Therapeutics (KPTI)
The company has return on total asset (ROA) of (0.2705) % which means that it has lost $0.2705 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.9105) %, meaning that it created substantial loss on money invested by shareholders. Karyopharm Therapeutics' management efficiency ratios could be used to measure how well Karyopharm Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The Karyopharm Therapeutics' current Return On Equity is estimated to increase to 1.10, while Return On Tangible Assets are projected to decrease to (0.62). As of now, Karyopharm Therapeutics' Other Current Assets are increasing as compared to previous years. The Karyopharm Therapeutics' current Debt To Assets is estimated to increase to 0.76, while Total Assets are projected to decrease to under 238.3 M. The firm currently falls under 'Small-Cap' category with a current market capitalization of 126.95 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Karyopharm Therapeutics's market, we take the total number of its shares issued and multiply it by Karyopharm Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Today, the firm appears to be overvalued. Karyopharm Therapeutics secures a last-minute Real Value of $0.96 per share. The latest price of the firm is $1.09. Our model forecasts the value of Karyopharm Therapeutics from analyzing the firm fundamentals such as Return On Equity of -8.91, profit margin of (0.98) %, and Current Valuation of 243.48 M as well as examining its technical indicators and probability of bankruptcy. In general, most investors recommend purchasing undervalued stocks and trading away overvalued stocks since, at some point, asset prices and their ongoing real values will merge together.
Merrimack Pharmaceuticals (MACK)
The company has return on total asset (ROA) of (0.0697) % which means that it has lost $0.0697 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0622) %, meaning that it created substantial loss on money invested by shareholders. Merrimack Pharmaceuticals' management efficiency ratios could be used to measure how well Merrimack Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.06. Return On Capital Employed is expected to rise to -0.11 this year. Change To Liabilities is expected to rise to about 25.5 K this year, although the value of Total Current Liabilities will most likely fall to about 418.9 K. This firm currently falls under 'Small-Cap' category with a current market capitalization of 213.98 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Merrimack Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Merrimack Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce. View Profile
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Please refer to our Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com
Did you try this?
Run Portfolio File Import Now
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any private could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
